Literature DB >> 31734891

The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.

L Di Luigi1,2, F Pigozzi3, P Sgrò3, L Frati4,5, A Di Gianfrancesco3,4, M Cappa4,6.   

Abstract

To protect sporting ethics and athletes' health, the World Anti-Doping Agency (WADA) produced the World Anti-Doping Code and The Prohibited List of substances and methods forbidden in sports. In accordance with the International Standards for Therapeutic Use Exemption (ISTUE), to avoid rule violations and sanctions, athletes affected by different endocrine diseases and disorders (e.g., adrenal insufficiency, diabetes, male hypogonadisms, pituitary deficit, thyroid diseases, etc.) who need to use a prohibited substance for therapeutic reasons (e.g., medical treatments, surgical procedures, clinical diagnostic investigations) must apply to their respective Anti-Doping Organizations (ADOs) to obtain a Therapeutic Use Exemption (TUE), if specific criteria are respected. The physicians who treat these athletes (i.e., endocrinologists, andrologists and diabetologists) are highly involved in these procedures and should be aware of their specific role and responsibility in applying for a TUE, and in adequately monitoring unhealthy athletes treated with prohibited substances. In this paper, the prohibited substances commonly used for therapeutic reasons in endocrine diseases and disorders (e.g., corticotropins, beta-blockers, glucocorticoids, hCG, insulin, GnRH, rhGH, testosterone, etc.), the role of physicians in the TUE application process and the general criteria used by ADO-Therapeutic Use Exemption Committees (TUECs) for granting a TUE are described.

Entities:  

Keywords:  Doping; Glucocorticoids; Growth hormone; Hypogonadism; Sport; TUE; Testosterone; Transgender; WADA

Mesh:

Substances:

Year:  2019        PMID: 31734891     DOI: 10.1007/s40618-019-01145-z

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  43 in total

Review 1.  Proscribed drugs at the Olympic Games: permitted use and misuse (doping) by athletes.

Authors:  Ken Fitch
Journal:  Clin Med (Lond)       Date:  2012-06       Impact factor: 2.659

2.  Long-term response to recombinant human growth hormone treatment: a new predictive mathematical method.

Authors:  G Migliaretti; S Ditaranto; C Guiot; S Vannelli; P Matarazzo; N Cappello; I Stura; F Cavallo
Journal:  J Endocrinol Invest       Date:  2018-01-09       Impact factor: 4.256

3.  Ethical practice and sports physician protection: a proposal.

Authors:  Søren Holm; Michael J McNamee; Fabio Pigozzi
Journal:  Br J Sports Med       Date:  2011-06-03       Impact factor: 13.800

4.  Make Sport Great Again: The Use and Abuse of the Therapeutic Use Exemptions Process.

Authors:  Yannis Pitsiladis; Guan Wang; Alain Lacoste; Christian Schneider; Angela D Smith; Alessia Di Gianfrancesco; Fabio Pigozzi
Journal:  Curr Sports Med Rep       Date:  2017 May/Jun       Impact factor: 1.733

5.  The use of follicle stimulating hormone (FSH) for the treatment of the infertile man: position statement from the Italian Society of Andrology and Sexual Medicine (SIAMS).

Authors:  A Barbonetti; A E Calogero; G Balercia; A Garolla; C Krausz; S La Vignera; F Lombardo; E A Jannini; M Maggi; A Lenzi; C Foresta; A Ferlin
Journal:  J Endocrinol Invest       Date:  2018-02-01       Impact factor: 4.256

Review 6.  15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2019.

Authors: 
Journal:  Diabetes Care       Date:  2019-01       Impact factor: 19.112

Review 7.  Testosterone Deficiency: A Review and Comparison of Current Guidelines.

Authors:  Jethro C C Kwong; Yonah Krakowsky; Ethan Grober
Journal:  J Sex Med       Date:  2019-05-09       Impact factor: 3.802

8.  Do non-steroidal anti-inflammatory drugs influence the steroid hormone milieu in male athletes?

Authors:  L Di Luigi; C Rossi; P Sgrò; V Fierro; F Romanelli; C Baldari; L Guidetti
Journal:  Int J Sports Med       Date:  2007-05-11       Impact factor: 3.118

9.  The type 5 phosphodiesterase inhibitor tadalafil influences salivary cortisol, testosterone, and dehydroepiandrosterone sulphate responses to maximal exercise in healthy men.

Authors:  Luigi Di Luigi; Carlo Baldari; Paolo Sgrò; Gian Pietro Emerenziani; Maria Chiara Gallotta; Serena Bianchini; Francesco Romanelli; Fabio Pigozzi; Andrea Lenzi; Laura Guidetti
Journal:  J Clin Endocrinol Metab       Date:  2008-06-17       Impact factor: 5.958

10.  Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS).

Authors:  V Rochira; G Mossetto; N Jia; S Cannavo; P Beck-Peccoz; G Aimaretti; M R Ambrosio; C Di Somma; M Losa; D Ferone; C Lubrano; C Scaroni; A Giampietro; S M Corsello; M Poggi
Journal:  J Endocrinol Invest       Date:  2018-03-13       Impact factor: 4.256

View more
  2 in total

1.  Attitudes and Associated Demographic Factors Contributing towards the Abuse of Illicit Drugs: A Cross-Sectional Study from Health Care Students in Saudi Arabia.

Authors:  Wajid Syed; Ayesha Iqbal; Nasir A Siddiqui; Ramzi A Mothana; Omer Noman
Journal:  Medicina (Kaunas)       Date:  2022-02-21       Impact factor: 2.430

Review 2.  Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge.

Authors:  Matti L Gild; Mark Stuart; Roderick J Clifton-Bligh; Audrey Kinahan; David J Handelsman
Journal:  J Clin Endocrinol Metab       Date:  2022-08-18       Impact factor: 6.134

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.